MYOV Myovant Science

Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study

Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study

BRISBANE, Calif. and BASEL, Switzerland, July 22, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Tuesday, July 23, 2019, to discuss results from the Phase 3 LIBERTY 2 study of once-daily relugolix combination therapy in women with uterine fibroids and heavy menstrual bleeding. The company will also discuss results from a separate bioequivalence study comparing single-tablet relugolix combination therapy with the two-tablet regimen used in the LIBERTY clinical program. 

Webcast/Teleconference Details

To participate in the live conference call, please dial 1-800-532-3746 for domestic callers and 1- 470-495-9166 for international callers. A live webcast of the conference call will also be available on the investor relations page of Myovant’s website at . After the live webcast, the event will remain archived on Myovant’s website for at least 30 days.

About Myovant Sciences

Myovant Sciences aspires to be the leading healthcare company focused on innovative treatments for women's health and prostate cancer. Myovant's lead product candidate is relugolix, an oral once-daily small molecule that acts as a GnRH receptor antagonist. Myovant has three late-stage clinical programs for relugolix ongoing in uterine fibroids, endometriosis and prostate cancer. Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and prostate cancer. For more information, please visit Myovant's website at . Follow @Myovant on Twitter and LinkedIn ().

Investor Contact:

Frank Karbe

Chief Financial Officer

Myovant Sciences, Inc.

Media Contact:

Sheryl Seapy

Pure Communications



949.903.4750

EN
22/07/2019

Underlying

MYOVMyovant Science

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myovant Science

 PRESS RELEASE
Free
MYOV MYOVANT SCIENCE

Myovant Sciences Announces Corporate Updates and Financial Results for...

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima...

January 26, 2023 1 EN
 PRESS RELEASE
Free
MYOV MYOVANT SCIENCE

Myovant Sciences Announces New Employment Inducement Grants Under NYSE...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual ...

November 16, 2022 1 EN
 PRESS RELEASE
Free
MYOV MYOVANT SCIENCE

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human...

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a...

November 16, 2022 1 EN
 PRESS RELEASE
Free
MYOV MYOVANT SCIENCE

Myovant Sciences Announces Corporate Updates and Financial Results for...

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billio...

October 26, 2022 1 EN
 PRESS RELEASE
Free
MYOV MYOVANT SCIENCE

Myovant Sciences Cancels Second Quarter Earnings Conference Call

Myovant Sciences Cancels Second Quarter Earnings Conference Call BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, a...

October 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch